KR20230015939A - 비알콜성 지방간염 (nash) 의 치료 - Google Patents

비알콜성 지방간염 (nash) 의 치료 Download PDF

Info

Publication number
KR20230015939A
KR20230015939A KR1020227043976A KR20227043976A KR20230015939A KR 20230015939 A KR20230015939 A KR 20230015939A KR 1020227043976 A KR1020227043976 A KR 1020227043976A KR 20227043976 A KR20227043976 A KR 20227043976A KR 20230015939 A KR20230015939 A KR 20230015939A
Authority
KR
South Korea
Prior art keywords
25hc3s
salt
day
subject
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227043976A
Other languages
English (en)
Korean (ko)
Inventor
웨이치 린
Original Assignee
듀렉트 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 듀렉트 코퍼레이션 filed Critical 듀렉트 코퍼레이션
Publication of KR20230015939A publication Critical patent/KR20230015939A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR1020227043976A 2020-05-22 2021-05-21 비알콜성 지방간염 (nash) 의 치료 Pending KR20230015939A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029361P 2020-05-22 2020-05-22
US63/029,361 2020-05-22
US202063030207P 2020-05-26 2020-05-26
US63/030,207 2020-05-26
US202063113116P 2020-11-12 2020-11-12
US63/113,116 2020-11-12
US202163146555P 2021-02-05 2021-02-05
US63/146,555 2021-02-05
PCT/US2021/033743 WO2021237143A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (1)

Publication Number Publication Date
KR20230015939A true KR20230015939A (ko) 2023-01-31

Family

ID=78707644

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227043976A Pending KR20230015939A (ko) 2020-05-22 2021-05-21 비알콜성 지방간염 (nash) 의 치료

Country Status (11)

Country Link
US (1) US20230181601A1 (https=)
EP (1) EP4153164A4 (https=)
JP (1) JP2023527153A (https=)
KR (1) KR20230015939A (https=)
CN (1) CN115916181A (https=)
AU (1) AU2021273936A1 (https=)
BR (1) BR112022022737A2 (https=)
CA (1) CA3195103A1 (https=)
MX (1) MX2022014575A (https=)
TW (1) TW202210081A (https=)
WO (1) WO2021237143A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
SG11201507288UA (en) * 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US20200222430A1 (en) * 2016-08-02 2020-07-16 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
CN110536682B (zh) * 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
KR102419458B1 (ko) * 2017-10-06 2022-07-12 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법

Also Published As

Publication number Publication date
CA3195103A1 (en) 2021-11-25
TW202210081A (zh) 2022-03-16
MX2022014575A (es) 2022-12-15
AU2021273936A1 (en) 2022-12-08
JP2023527153A (ja) 2023-06-27
BR112022022737A2 (pt) 2023-01-31
CN115916181A (zh) 2023-04-04
EP4153164A4 (en) 2024-06-26
US20230181601A1 (en) 2023-06-15
WO2021237143A1 (en) 2021-11-25
EP4153164A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
JP2021063088A (ja) 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法
JP7022136B2 (ja) 非アルコール性脂肪性肝炎の治療のための方法及び医薬組成物
CA3125341A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
US20220288053A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
KR20230015940A (ko) 비알콜성 지방간염 (nash) 의 치료
TW202128184A (zh) 酒精性肝炎之治療
KR20230015939A (ko) 비알콜성 지방간염 (nash) 의 치료
AU2018375298A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2022235647A1 (en) Methods for reducing liver fat and for treating fatty liver disorders
TW202214256A (zh) 非酒精性脂肪肝炎（ｎａｓｈ）之治療
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗
HK40089967A (zh) 非酒精性脂肪性肝炎(nash)的治疗
US20220193065A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Aslangul et al. Successful etanercept treatment of constrictive pericarditis complicating rheumatoid arthritis
BR122025021620A2 (pt) Composição compreendendo 25hc3s ou seu sal no tratamento de hepatite alcoólica
US20220175758A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2023210716A1 (ja) Ｃｂｐ／カテニン阻害剤の肝線維症治療レジメン
WO2014201038A1 (en) Treating inflammatory bowel disease or chronic pancreatitis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902